Structure‑activity relationship of 1‑desamino‑8‑D‑arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor‑expressing cancer cells

Pastrian,María B.; Guzmán,Fanny; Garona,Juan; Pifano,Marina; Ripoll,Giselle V.; Cascone,Osvaldo; Ciccia,Graciela N.; Albericio,Fernando; Gómez,Daniel E.; Alonso,Daniel F.; Iannucci,Nancy B.

doi:10.3892/mmr.2014.2140

Structure‑activity relationship of 1‑desamino‑8‑D‑arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor‑expressing cancer cells

Authors:
- María B. Pastrian
- Fanny Guzmán
- Juan Garona
- Marina Pifano
- Giselle V. Ripoll
- Osvaldo Cascone
- Graciela N. Ciccia
- Fernando Albericio
- Daniel E. Gómez
- Daniel F. Alonso
- Nancy B. Iannucci
View Affiliations

Affiliations: School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina, Biotechnology Nucleus, Pontifical Catholic University of Valparaiso, Valparaiso, Chile, Laboratory of Molecular Oncology, Quilmes National University, Buenos Aires, Argentina, Therapeutic Peptides Research and Development Laboratory, Chemo‑Romikin, Buenos Aires, Argentina, Institute for Research in Biomedicine, Barcelona Science Park, Barcelona, Spain
Published online on: April 11, 2014 https://doi.org/10.3892/mmr.2014.2140
Pages: 2568-2572

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The synthetic nonapeptide 1‑desamino‑8‑D‑arginine vasopressin (dDAVP) can reduce tumor cell growth through agonist action on the vasopressin V2 receptor. A structure‑antiproliferative activity relationship analysis of dDAVP was performed using the alanine scanning technique on the aggressive MDA‑MB‑231 human breast carcinoma cell line. The results from this analysis demonstrated that the amino acids located at the loop of dDAVP are important for the antiproliferative activity of dDAVP, highlighting the key role of the N‑terminal region of the peptide in the interaction with the tumor cell surface receptor. The findings from this study present novel strategies for designing improved compounds with enhanced stability for cancer therapy.

View Figures

View References

1	Manning M, Stoev S, Chini B, Durroux T, Mouillac B and Guillon G: Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 ant OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 170:473–512. 2008. View Article : Google Scholar : PubMed/NCBI
2	Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M and Guillon G: Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol. 24:609–628. 2012. View Article : Google Scholar : PubMed/NCBI
3	North WG, Fay MJ and Du J: MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R. Peptides. 20:837–842. 1999. View Article : Google Scholar : PubMed/NCBI
4	Ripoll GV, Giron S, Krzymuski MJ, Hermo GA, Gomez DE and Alonso DF: Antitumor effects of desmopressin in combination with chemotherapeutic agents in a mouse model of breast cancer. Anticancer Res. 28:2607–2611. 2008.PubMed/NCBI
5	Alonso DF, Ripoll GV, Garona J, Iannucci NB and Gomez DE: Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin. Curr Pharm Biotech. 12:1974–1980. 2011. View Article : Google Scholar
6	Cunningham BC and Wells JA: High-resolution epitope mapping of hGH receptor interactions by alanine-scanning mutagenesis. Science. 244:1081–1085. 1989. View Article : Google Scholar : PubMed/NCBI
7	Beck-Sickinger AG, Wieland HA, Wittneben H, Willim KD, Rudolf K and Jung G: Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations. Eur J Biochem. 225:947–958. 1994. View Article : Google Scholar : PubMed/NCBI
8	Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, Couvineau A, Martínez J, Brasseur R and Laburthe M: Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem. 275:24003–24012. 2000. View Article : Google Scholar
9	Quartara L, Ricci R, Meini S, et al: Ala scan analogues of HOE 140. Synthesis and biological activities. Eur J Med Chem. 35:1001–1010. 2000. View Article : Google Scholar : PubMed/NCBI
10	Nam J, Shin D, Rew Y and Boger DL: Alanine scan of [L-Dap(2)]ramoplanin A2 aglycon: assessment of the importance of each residue. J Am Chem Soc. 129:8747–8755. 2007.
11	Houghten RA: General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA. 82:5131–5135. 1985. View Article : Google Scholar
12	Albericio F, Annis I, Royo M and Barany G: Preparation and handling of peptides containing methionine and cysteine. Fmoc Solid Phase Peptide Synthesis. A Practical Approach. Chan WC and White PD: Oxford University Press Inc; New York, NY: pp. 77–114. 2000
13	Czaplewski C, Kázmierkiewicz R and Ciarkowski J: Molecular modeling of the human vasopressin V2 receptor/agonist complex. J Comp Aided Mol Des. 12:275–287. 1998. View Article : Google Scholar : PubMed/NCBI
14	Iannucci NB, Ripoll GV, Garona J, Cascone O, Ciccia GN, Gomez DE and Alonso DF: Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells. Future Med Chem. 3:1987–1993. 2011. View Article : Google Scholar : PubMed/NCBI
15	Kowalczyk W, Prahl A, Derdowska I, Sobolewski D, Olejnik J, Zabrocki J, Borovicková L, Slaninová J and Lammek B: Analogues of neurohypophyseal hormones, oxytocin and arginine vasopressin, conformationally restricted in the N-terminal part of the molecule. J Med Chem. 49:2016–2021. 2006. View Article : Google Scholar
16	North WG, Pai S, Friedmann A, Yu X, Fay M and Memoli V: Vasopressin gene related products are markers of human breast cancer. Breast Cancer Res Treat. 34:229–235. 1995. View Article : Google Scholar : PubMed/NCBI
17	Monstein HJ, Truedsson M, Ryberg A and Ohlsson B: Vasopressin receptor mRNA expression in the human gastrointestinal tract. Eur Surg Res. 40:34–40. 2008. View Article : Google Scholar : PubMed/NCBI
18	North WG, Fay MJ, Longo KA and Du J: Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide. Cancer Res. 58:1866–1871. 1998.PubMed/NCBI
19	Terraube V, Pendu R, Baruch D, Gebbink MF, Meyer D, Lenting PJ and Denis CV: Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost. 4:519–526. 2006. View Article : Google Scholar : PubMed/NCBI
20	Mochizuki S, Soejima K, Shimoda M, Abe H, Sasaki A, Okano HJ, Okano H and Okada Y: Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst. 104:906–922. 2012. View Article : Google Scholar : PubMed/NCBI
21	Colgrave ML and Craik DJ: Thermal, chemical and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. Biochemistry. 43:5965–5975. 2004. View Article : Google Scholar : PubMed/NCBI
22	Craik DJ, Cemazar M and Daly NL: The cyclotides and related macrocyclic peptides as scaffolds in drug design. Curr Opin Drug Discovery Devel. 9:251–260. 2006.PubMed/NCBI